Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics

Petros Pharmaceuticals Inc. (PTPI): $1.51

0.02 (-1.31%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

PTPI Price/Volume Stats

Current price $1.51 52-week high $9.54
Prev. close $1.53 52-week low $0.92
Day low $1.50 Volume 12,300
Day high $1.58 Avg. volume 1,036,500
50-day MA $2.92 Dividend yield N/A
200-day MA $2.70 Market Cap 3.15M

PTPI Stock Price Chart Interactive Chart >

PTPI POWR Grades

  • Value is the dimension where PTPI ranks best; there it ranks ahead of 74.52% of US stocks.
  • PTPI's strongest trending metric is Value; it's been moving down over the last 91 days.
  • PTPI ranks lowest in Stability; there it ranks in the 0th percentile.

PTPI Stock Summary

  • With a market capitalization of $3,709,315, PETROS PHARMACEUTICALS INC has a greater market value than only 1.84% of US stocks.
  • Revenue growth over the past 12 months for PETROS PHARMACEUTICALS INC comes in at -51.42%, a number that bests merely 5.03% of the US stocks we're tracking.
  • PETROS PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 34.19%, greater than the shareholder yield of 94.56% of stocks in our set.
  • Stocks that are quantitatively similar to PTPI, based on their financial statements, market capitalization, and price volatility, are FLNT, GOCO, VCSA, BZFD, and TEVA.
  • To dig deeper into the stock's financial statements, go to PTPI's page on browse-edgar?action=getcompany&CIK=0001815903.

PTPI Valuation Summary

  • PTPI's EV/EBIT ratio is -0.2; this is 101.61% lower than that of the median Healthcare stock.
  • Over the past 34 months, PTPI's EV/EBIT ratio has gone up 2.4.

Below are key valuation metrics over time for PTPI.

Stock Date P/S P/B P/E EV/EBIT
PTPI 2023-09-18 1.0 0.3 -0.2 -0.2
PTPI 2023-09-15 1.0 0.3 -0.2 -0.2
PTPI 2023-09-14 1.0 0.3 -0.2 -0.2
PTPI 2023-09-13 1.1 0.3 -0.2 -0.3
PTPI 2023-09-12 1.1 0.3 -0.2 -0.3
PTPI 2023-09-11 1.0 0.3 -0.2 -0.3

Petros Pharmaceuticals Inc. (PTPI) Company Bio


Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.


PTPI Latest News Stream


Event/Time News Detail
Loading, please wait...

PTPI Latest Social Stream


Loading social stream, please wait...

View Full PTPI Social Stream

Latest PTPI News From Around the Web

Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.

Petros Pharmaceuticals Provides Letter to Shareholders

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:

Yahoo | September 11, 2023

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/ Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

Yahoo | September 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!

William White on InvestorPlace | July 14, 2023

Petros Pharmaceuticals Announces Capital Raise of $15 Million

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status.

Yahoo | July 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning!

William White on InvestorPlace | April 17, 2023

Read More 'PTPI' Stories Here

PTPI Price Returns

1-mo -43.87%
3-mo -24.50%
6-mo 4.14%
1-year -67.83%
3-year N/A
5-year N/A
YTD -35.19%
2022 -93.00%
2021 -24.32%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!